Advanced Medical Solutions Group (LON:AMS) Releases Earnings Results

Advanced Medical Solutions Group (LON:AMS) announced its quarterly earnings data on Thursday. The company reported GBX 10.65 ($0.14) earnings per share for the quarter, Digital Look Earnings reports. Advanced Medical Solutions Group had a return on equity of 4.57% and a net margin of 8.49%.

Advanced Medical Solutions Group Price Performance

AMS stock traded down GBX 3.50 ($0.05) during mid-day trading on Friday, reaching GBX 201 ($2.61). 1,740,479 shares of the company’s stock were exchanged, compared to its average volume of 862,780. The company has a market cap of £434.01 million, a price-to-earnings ratio of 38.95, a price-to-earnings-growth ratio of 5.00 and a beta of 0.74. The stock’s 50 day moving average is GBX 211.58 and its 200 day moving average is GBX 212.49. The company has a debt-to-equity ratio of 37.01, a current ratio of 8.39 and a quick ratio of 4.58. Advanced Medical Solutions Group has a 12-month low of GBX 176.60 ($2.29) and a 12-month high of GBX 275.83 ($3.58).

Advanced Medical Solutions Group Increases Dividend

The firm also recently declared a dividend, which will be paid on Friday, June 20th. Shareholders of record on Thursday, May 29th will be given a dividend of GBX 1.83 ($0.02) per share. The ex-dividend date of this dividend is Thursday, May 29th. This represents a yield of 0.89%. This is an increase from Advanced Medical Solutions Group’s previous dividend of $0.77. Advanced Medical Solutions Group’s dividend payout ratio is currently 38.76%.

Analysts Set New Price Targets

Separately, Berenberg Bank restated a “buy” rating and issued a GBX 300 ($3.89) target price on shares of Advanced Medical Solutions Group in a research note on Wednesday.

About Advanced Medical Solutions Group

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, and Seal-G®.